Synpromics
Company that develops and commercializes synthetic promoters to control gene expressions and regulations
Synpromics is the leader in gene control, improving human health by enabling safer, more effective cell and gene medicines through proprietary genomics, bioinformatics and intelligent data driven design. Synpromics enables unprecedented control of gene expression through its ability to custom design synthetic cell-type, or condition, specific promoters. We achieve this by using proprietary technology and cutting edge techniques including sophisticated bioinformatics and screening approaches.
Purchased by AskBio on 13-Aug-2019
Visit website: https://www.synpromics.com/
Details last updated 03-Oct-2019
Mentioned in this Resource
Asklepios BioPharmaceutical (AskBio)
Clinical-stage AAV gene therapy company for patients with rare diseases and other disorders
Synpromics News
Targeting Senescent Cells with Synthetic Biology
Lifespan.io (LEAF) - 09-Dec-2016
CellAge is going to develop synthetic promoters which are specific to senescent cells, as promote...
Read more...